Participant flow

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers · Source last updated 2025-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.

   id

   FG000

   title

   Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)

2. description

   Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.

   id

   FG001

   title

   Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)

3. description

   Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.

   id

   FG002

   title

   Cohort 12 - Gastric (Budigalimab + mFOLFOX6)

4. description

   Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.

   id

   FG003

   title

   Cohort 3A - Gastric (TTX-030 + mFOLFOX6)

5. description

   Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375 mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.

   id

   FG004

   title

   Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)

6. description

   Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.

   id

   FG005

   title

   Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)

7. description

   Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.

   id

   FG006

   title

   Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)

8. description

   Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.

   id

   FG007

   title

   Cohort 4 - CRC (TTX-030 + Budigalimab)

9. description

   Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.

   id

   FG008

   title

   Cohort 6 - HNSCC (TTX-030 + Budigalimab)

10. description

    Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.

    id

    FG009

    title

    Cohort 8 - GEC (TTX-030 + Budigalimab)

11. description

    Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.

    id

    FG010

    title

    Cohort 10 - UCC (TTX-030 + Pembrolizumab)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         44

      3. group Id

         FG002

         num Subjects

         25

      4. group Id

         FG003

         num Subjects

         6

      5. group Id

         FG004

         num Subjects

         7

      6. group Id

         FG005

         num Subjects

         28

      7. group Id

         FG006

         num Subjects

         17

      8. group Id

         FG007

         num Subjects

         14

      9. group Id

         FG008

         num Subjects

         5

      10. group Id

          FG009

          num Subjects

          23

      11. group Id

          FG010

          num Subjects

          8

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         44

      3. group Id

         FG002

         num Subjects

         25

      4. group Id

         FG003

         num Subjects

         6

      5. group Id

         FG004

         num Subjects

         7

      6. group Id

         FG005

         num Subjects

         28

      7. group Id

         FG006

         num Subjects

         17

      8. group Id

         FG007

         num Subjects

         14

      9. group Id

         FG008

         num Subjects

         5

      10. group Id

          FG009

          num Subjects

          23

      11. group Id

          FG010

          num Subjects

          8

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         0

      10. group Id

          FG009

          num Subjects

          0

      11. group Id

          FG010

          num Subjects

          0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice